



A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

1. diagnosis of inflammatory breast cancer without distant metastases 2. completed neoadjuvant chemotherapy prior to mastectomy 3. radiation therapy has not been given to the affected breast 4. able to swallow and retain oral medications and have no known gastrointestinal disorders likely to interfere with absorption of the study medication

Exclusion Criteria:

1. active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia. 2. history of uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or extensive interstitial bilateral lung disease

Conditions & Interventions

Conditions:

Cancer

Keywords:

Breast Cancer, Breast Cancer, Inflammatory Breast Cancer

More Information

Description: We are studying how well radiation therapy with or without olaparib works in treating people with inflammatory breast cancer. Olaparib may keep cancer cells from repairing themselves, making them die. We want to see if adding this drug to radiation therapy is more effective.

Study Contact: Kristen Nelson - knelso65@fairview.org

Principal Investigator: Kiran Lassi

IRB

Number: MMCORC051

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.